20-Feb-2026
Earnings week ahead: NVDA, CRM, HD, BIDU, LOW, DELL, SNOW, AMC, ZM, and more
Seeking Alpha News (Sun, 22-Feb 8:07 AM ET)
Business Wire (Wed, 4-Feb 4:05 PM ET)
Business Wire (Mon, 2-Feb 4:05 PM ET)
Business Wire (Tue, 13-Jan 9:00 AM ET)
Business Wire (Thu, 18-Dec 4:05 PM ET)
Business Wire (Fri, 12-Dec 8:00 AM ET)
Acadia’s Phase 3 COMPASS PWS Trial Falls Short—but Pipeline and Revenue Projections Remain Strong
Market Chameleon (Wed, 24-Sep 3:57 AM ET)
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Acadia Pharmaceuticals trades on the NASDAQ stock market under the symbol ACAD.
As of February 20, 2026, ACAD stock price declined to $23.99 with 1,950,005 million shares trading.
ACAD has a beta of 1.13, meaning it tends to be more sensitive to market movements. ACAD has a correlation of 0.17 to the broad based SPY ETF.
ACAD has a market cap of $4.02 billion. This is considered a Mid Cap stock.
Last quarter Acadia Pharmaceuticals reported $279 million in Revenue and $.26 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.12.
In the last 3 years, ACAD traded as high as $33.99 and as low as $13.40.
The top ETF exchange traded funds that ACAD belongs to (by Net Assets): IJR, VTI, XBI, FBT, IWM.
ACAD has outperformed the market in the last year with a price return of +18.2% while the SPY ETF gained +14.1%. However, in the short term, ACAD had mixed performance relative to the market. It has underperformed in the last 3 months, returning +4.8% vs +6.0% return in SPY. But in the last 2 weeks, ACAD shares have fared better than the market returning +1.8% compared to SPY -0.2%.
ACAD support price is $23.60 and resistance is $25.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACAD shares will trade within this expected range on the day.
